Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic
db/db mice.
Authors
Reddy MA, Sumanth P, Lanting L, Yuan H, Wang M, Mar D, Alpers CE, Bomsztyk K,
Natarajan R
Submitted By
Submitted Externally on 12/20/2013
Status
Published
Journal
Kidney international
Year
2013
Date Published
10/2/2013
Volume : Pages
85 : 362 - 373
PubMed Reference
24088954
Abstract
Epigenetic mechanisms such as chromatin histone H3 lysine methylation and
acetylation have been implicated in diabetic vascular complications. However,
histone modification profiles at pathologic genes associated with diabetic
nephropathy in vivo and their regulation by the angiotensin II type 1 receptor
(AT1R) are not clear. Here we tested whether treatment of type 2 diabetic db/db
mice with the AT1R blocker losartan not only ameliorates diabetic nephropathy,
but also reverses epigenetic changes. As expected, the db/db mice had increased
blood pressure, mesangial hypertrophy, proteinuria, and glomerular expression of
RAGE and PAI-1 vs. control db/+ mice. This was associated with increased RNA
polymerase II recruitment and permissive histone marks as well as decreased
repressive histone marks at these genes, and altered expression of relevant
histone modification enzymes. Increased MCP-1 mRNA levels were not associated
with such epigenetic changes, suggesting post-transcriptional regulation.
Losartan attenuated key parameters of diabetic nephropathy and gene expression,
and reversed some but not all the epigenetic changes in db/db mice. Losartan
also attenuated increased H3K9/14Ac at RAGE, PAI-1, and MCP-1 promoters in
mesangial cells cultured under diabetic conditions. Our results provide novel
information about the chromatin state at key pathologic genes in vivo in
diabetic nephropathy mediated in part by AT1R. Thus, combination therapies
targeting epigenetic regulators and AT1R could be evaluated for more effective
treatment of diabetic nephropathy.Kidney International advance online
publication, 2 October 2013; doi:10.1038/ki.2013.387.
Investigators with authorship
Name
Institution
Charles Alpers
University of Washington
Karol Bomsztyk
University of Washington
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!